News Daily News OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer L.A. McKeown December 16, 2022
News Daily News Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS Todd Neale December 01, 2022
News Daily News Slight Risk of Interstitial Lung Disease Seen With Certain DOACs Todd Neale November 23, 2022
News Daily News Apixaban Again Linked to Less Bleeding in AF Patients Michael O'Riordan October 31, 2022
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
News Conference News TCT 2022 RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion Todd Neale September 21, 2022
Presentation TCT 2022 Prevention of Radial Artery Occlusion With Rivaroxaban After Transradial Coronary Procedures: The RIVARAD Multicentric Randomized Trial Presenter: Rania Hammami September 19, 2022
News Conference News TCT 2022 As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant Michael O'Riordan September 18, 2022
News Conference News ESC 2022 COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19 Todd Neale September 01, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2022 Shelley Wood September 01, 2022
Presentation ESC 2022 Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial Presenter: Sanjit Jolly August 28, 2022
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
Podcast TCTMD Talking Points Stopping Amputation Post-revascularization: Novel Data in Mitigation of Thrombosis Risk July 06, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for June 2022 Caitlin E. Cox July 04, 2022
News Daily News Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients L.A. McKeown June 29, 2022
News Daily News Subclinical Thrombosis After TAVI Benign, at Least to 3 Years Michael O'Riordan June 07, 2022